Examkin

Soru

Zorluk: OrtaDepressive Disorders

A 42-year-old man presents to the psychiatric clinic for the management of a newly diagnosed major depressive disorder (MDD). Over the next 18 months, his clinical course is characterized by significant treatment resistance, eventually leading to a severe exacerbation with psychotic features and food refusal. Arrange the following therapeutic interventions in the correct chronological order according to standard stepped-care pharmacologic and somatic treatment guidelines for MDD, starting from his initial presentation to his most severe exacerbation.

  1. 1Initiate monotherapy with a first-line selective serotonin reuptake inhibitor (SSRI) and titrate to a therapeutic dose.
  2. 2Switch to a different class of antidepressant, such as a serotonin-norepinephrine reuptake inhibitor (SNRI), following non-response to an adequate 6-week trial.
  3. 3Augment the current antidepressant regimen with a second-generation antipsychotic (e.g., aripiprazole) or lithium due to persistent partial response.
  4. 4Administer electroconvulsive therapy (ECT) to rapidly address a severe depressive relapse complicated by mood-congruent delusions and severe oral intake restriction.

Cevap

The correct sequence of treatment escalation for major depressive disorder is: 1) initial SSRI/SNRI monotherapy, 2) switching to an alternative monotherapy upon non-response, 3) augmentation with a secondary agent (e.g., atypical antipsychotic) for partial response, and finally 4) electroconvulsive therapy for severe, treatment-resistant, or psychotic depression.
The correct sequence follows the evidence-based stepped-care model for MDD: initial monotherapy, switching monotherapies if there is no response, utilizing augmentation strategies if there is a partial response, and reserving electroconvulsive therapy for severe, refractory, or psychotic cases.

Adım Adım Çözüm

1
Identify the standard first-line treatment for uncomplicated MDD.
Initiation of SSRI monotherapy.
SSRIs have a favorable side effect profile and are the standard initial pharmacotherapy for MDD.
2
Determine the next step for a patient with zero response to an adequate initial trial.
Switching to a different antidepressant (e.g., SNRI).
Non-responders benefit more from switching to a different agent, whereas partial responders are candidates for augmentation.
3
Determine the management for a patient showing partial response to a subsequent monotherapy.
Augmentation with a second-generation antipsychotic or lithium.
Augmentation strategies build upon the partial efficacy of the current regimen to achieve remission in treatment-resistant cases.
4
Identify the definitive treatment for severe depression with life-threatening psychotic features.
Electroconvulsive therapy (ECT).
ECT provides rapid, highly effective relief for psychotic depression and when a patient's health is acutely compromised (e.g., food refusal).

Anahtar Kavram

The stepped-care approach to Major Depressive Disorder escalates from initial monotherapy, to switching agents for non-response, to augmentation for partial response, and ultimately to electroconvulsive therapy for refractory or psychotic depression.
Bu soruyu puanla

Konular

Depressive Disorders

Bu konudan daha fazla soru